Clinical Trials Logo

Solid Cancer clinical trials

View clinical trials related to Solid Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03721679 Terminated - Solid Cancer Clinical Trials

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Start date: September 25, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open labeled, non-randomized adaptive pilot study. The study interventions involved in this study are: Poly-ICLC (Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose, also known as Hiltonol®) treatment in combination with anti-PD-1 (Nivolumab, Cemiplimab or Pembrolizumab) or anti-PD-L1 (Atezolizumab or Durvalumab)